Uncovering negative results: Introducing an open access journal "Journal of Pharmaceutical Negative Results"

Abstract

Pharmacognosy Magazine,2010,6,24,345-347.DOI:10.4103/0973-1296.71783Published:October 2010Type:Letters to EditorAuthors:Vipra Kundoor, and KK Mueen Ahmed Author(s) affiliations:Vipra Kundoor1, KK Mueen Ahmed2 1U. S. Food and Drug Administration, Rockville, Maryland, USA 2Department of Pharm Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, Kingdom of Saudi Arabia Abstract:Drug discovery nowadays is a highly innovative process by which new drugs are discovered and/or designed. It is expected that in the year 2010, at least 50% of all new approved drugs will come from the biopharmaceutical sector. The discovery and validation process is mostly carried out by new innovative and medium-sized companies. But, despite advances in technology and greater understanding of biological systems, drug discovery is still a lengthy process. Specialized drug discovery companies need an ideal business climate, that is, political, economic, and social conditions, to be able to cope with the entrepreneurial risks of drug development. Read More... Keywords:NilView:PDF (848.34 KB) Full Text